Ardelyx, Inc. (ARDX)
After hours:
| Previous close | 6.39 |
| Open | 6.48 |
| Bid | 6.41 x 800 |
| Ask | 6.45 x 1500 |
| Day's range | 6.39 - 6.66 |
| 52-week range | 3.16 - 10.13 |
| Volume | |
| Avg. volume | 5,533,820 |
| Market cap | 1.496B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.65 |
Simply Wall St.Ardelyx's (NASDAQ:ARDX) investors will be pleased with their favorable 91% return over the last five years
While Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders are probably generally happy, the stock hasn't had particularly good...
GlobeNewswireArdelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2024. To part
- GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on March 25, 2024, the compensation committee of the company’s board of directors granted a non-qualified stock option award to purchase 205,000 shares of its common stock and a restricted stock unit award for 160,000 shares in
